Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)


Results from this trial will be presented in a webinar on Wednesday 23 February at 11.00am CET

Sign-up link

Key points from this study:
• Achievement of the study’s primary endpoint, confirming glenzocimab’s
very favorable safety profile
• Reduction in the number of intracerebral hemorrhages and mortality
among patients treated with glenzocimab

Read the Press Release